Brian P Murray

Dr. Brian P Murray

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2018 in Clinical Toxicology
Verified
Journal Article
Closed access
JCJoseph E. Carpenter
Joseph E. Carpenter
BMBrian P Murray
Brian P Murray
CDCamille Dunkley
Camille Dunkley
ZKZiad N. Kazzi
Ziad N. Kazzi
MGMelissa H. Gittinger
Melissa H. Gittinger
Importance: Exposures to novel psychoactive substances are reported with increasing frequency in both the medical literature and the lay press. While the majority of reports describe synthetic cannabinoids and cathinones, a lesser understood family is the “designer benzodiazepines”. The current literature describing human exposures to these compounds is comprised of case reports and small case series. Objective: The primary objectives of this study are to describe epidemiologic trends and clinical effects of designer benzodiazepine use. Methods: Data regarding single agent exposures to designer benzodiazepines between 1 January 2014 and 31 December 2017 was obtained from the National Poison Data System. Substances queried include: adinazolam, clonazolam, cloniprazepam, diclazepam, etizolam, flubromazepam, flubromazolam, meclonazepam, nifoxipam, norflurazepam, and pyrazolam. Data was summarized descriptively. Results: 234 single agent exposures in 40 states were reported during the study period. The annual number of exposures increased each year, from 26 in 2014 to 112 in 2017, amounting to a 330% increase. The most common exposures were etizolam (n = 162) and clonazolam (n = 50). The most common clinical effects were drowsiness/lethargy (65%), and slurred speech (17%). 3% required intubation, 36% of cases required hospital admission, 22% to the intensive care unit. There was 1 death in the study population. Conclusions: The incidence of exposures to designer benzodiazepines is rising. Clinical effects are generally consistent with a sedative-hypnotic toxidrome. Severe effects, including death, seemed relatively uncommon in the study population.

15 October 2001 in Journal of Experimental Zoology
Verified
Journal Article
Closed access
PDF file
GLGrace A. Loredo
Grace A. Loredo
ABAlla Brukman
Alla Brukman
MHMatthew P. Harris
Matthew P. Harris
DKDavid Kagle
David Kagle
ELElizabeth E. Leclair
Elizabeth E. Leclair
SGScott Gilbert
Scott Gilbert

30 August 2019 in Journal of Medical Toxicology
Verified
Journal Article
Closed access
PDF file
JCJoseph Carpenter
Joseph Carpenter
BMBrian P Murray
Brian P Murray
SASukhshant Atti
Sukhshant Atti
TMTim P. Moran
Tim P. Moran
AYArthur Yancey
Arthur Yancey
BMBrent Morgan
Brent Morgan

6 November 2001 in Genesis
Verified
Journal Article
Closed access
PDF file
KCKaren Clark
Karen Clark
GBGünes Bender
Günes Bender
BMBrian P Murray
Brian P Murray
Kristen A. PanfilioKristen A. Panfilio
Kristen A. Panfilio
SCSteven Cook
Steven Cook
SGScott Gilbert
Scott Gilbert

1 August 2019 in The Journal of Emergency Medicine
Verified
Journal Article
Closed access
CDCamille A. Dunkley
Camille A. Dunkley
JCJoseph E. Carpenter
Joseph E. Carpenter
BMBrian P Murray
Brian P Murray
ESEmma Sizemore
Emma Sizemore
MWMatthew Wheatley
Matthew Wheatley
ASAlaina Steck
Alaina Steck

26 September 2023 in Environment International
Verified
Journal Article
Open access
HCHoward Chang
Howard Chang
HZHaisu Zhang
Haisu Zhang
ALAmanda D. Latimore
Amanda D. Latimore
BMBrian P Murray
Brian P Murray
RDRohan R. D'SOuza
Rohan R. D'SOuza
SEStefanie T. Ebelt
Stefanie T. Ebelt
Substance use disorder is a growing public health challenge in the United States. People who use drugs may be more vulnerable to ambient heat due to the effects of drugs on thermoregulation and their risk environment. There have been limited population-based studies of ambient temperature and drug-related morbidity. We examined short-term associations between daily ambient temperature and emergency department (ED) visits for use or overdose of amphetamine, cocaine and opioids in California during the period 2005 to 2019. Daily ZIP code-level maximum, mean, and minimum temperature exposures were derived from 1-km data Daymet products. A time-stratified case-crossover design was used to estimate cumulative non-linear associations of daily temperature for lag days 0 to 3. Stratified analyses by patient sex, race, and ethnicity were also conducted. The study included over 3.4 million drug-related ED visits. We found positive associations between daily temperature and ED visits for all outcomes examined. An increase in daily mean temperature from the 50th to the 95th percentile was associated with ED visits for amphetamine use (OR = 1.072, 95% CI: 1.058, 1.086), cocaine use (OR = 1.044, 95% CI: 1.021, 1.068 and opioid use (OR = 1.041, 95% CI: 1.025, 1.057). Stronger positive associations were also observed for overdose: amphetamine overdose (OR = 1.150, 95% CI: 1.085, 1.218), cocaine overdose (OR = 1.159, 95% CI: 1.053, 1.276), and opioid overdose (OR = 1.079, 95% CI: 1.054, 1.106). In summary, people who use stimulants and opioids may be a subpopulation sensitive to short-term higher ambient temperature. Mitigating heat exposure can be considered in harm reduction strategies in response to the substance use epidemic and global climate change.